close

For more than four decades, Fenwick & West LLP has helped some of the world’s most recognized companies become, and remain, market leaders. From emerging enterprises to large public corporations, our clients are leaders in the technology, life sciences and cleantech sectors and are fundamentally changing the world through rapid innovation.  MORE >

Fenwick & West was founded in 1972 in the heart of Silicon Valley—before “Silicon Valley” existed—by four visionary lawyers who left a top-tier New York law firm to pursue their shared belief that technology would revolutionize the business world and to pioneer the legal work for those technological innovations. In order to be most effective, they decided they needed to move to a location close to primary research and technology development. These four attorneys opened their first office in downtown Palo Alto, and Fenwick became one of the first technology law firms in the world.  MORE >

From our founding in 1972, Fenwick has been committed to promoting diversity and inclusion both within our firm and throughout the legal profession. For almost four decades, the firm has actively promoted an open and inclusive work environment and committed significant resources towards improving our diversity efforts at every level.  MORE >

At Fenwick, we are proud of our commitment to the community and to our culture of making a difference in the lives of individuals and organizations in the communities where we live and work. We recognize that providing legal services is not only an essential part of our professional responsibility, but also an excellent opportunity for our attorneys to gain valuable practical experience, learn new areas of the law and contribute to the community.  MORE >

Year after year, Fenwick & West is honored for excellence in the legal profession. Many of our attorneys are recognized as leaders in their respective fields, and our Corporate, Tax, Litigation and Intellectual Property Practice Groups consistently receive top national and international rankings, including:

  • Named Technology Group of the Year by Law360
  • Ranked the #1 firm worldwide for technology deals through Q3 2015
  • Nearly 20 percent of Fenwick partners are ranked by Chambers
  • Consistently ranked among the top 10 law firms in the U.S. for diversity
  • Recognized as having top mentoring and pro bono programs by Euromoney

MORE >

We take sustainability very seriously at Fenwick. Like many of our clients, we are adopting policies that reduce consumption and waste, and improve efficiency. By using technologies developed by a number of our cleantech clients, we are at the forefront of implementing sustainable policies and practices that minimize environmental impact. In fact, Fenwick has earned recognition in several areas as one of the top US law firms for implementing sustainable business practices.  MORE >

At Fenwick, we have a passion for excellence and innovation that mirrors our client base. Our firm is making revolutionary changes to the practice of law through substantial investments in proprietary technology tools and processes—allowing us to deliver best-in-class legal services more effectively.   MORE >

Mountain View Office
Silicon Valley Center
801 California Street
Mountain View, CA 94041
650.988.8500

San Francisco Office
555 California Street
12th Floor
San Francisco, CA 94104
415.875.2300

Seattle Office
1191 Second Avenue
10th Floor
Seattle, WA 98101
206.389.4510

Shanghai Office
Unit 908, 9/F, Kerry Parkside Office
No. 1155 Fang Dian Road
Pudong New Area, Shanghai 201204
P.R. China
+86 21 8017 1200

Kevin Kabler, Ph.D.

Associate, Intellectual Property

icon partner 415.875.2352

Kevin Kabler focuses his practice on building and managing patent portfolios for life science-focused clients. He prepares and prosecutes domestic and international patent applications in a wide range of technical fields, including immuno-oncology, antibodies, personalized medicine, vaccines, biologics, RNAi, clean-tech, stem cells, immunotherapy, and small molecules. His practice also involves strategic patent counseling and due diligence in the life sciences, including evaluating risks from third-party patents and assisting in efforts to reduce identified risks.

Kevin counsels and partners with all types of life science companies and institutions at all stages of the business cycle. He also assists investors in assessing the competitive landscape, technology, and intellectual property assets and risks associated with target investments.

Kevin began his career at Fenwick & West as a patent agent in 2007. Prior to joining Fenwick & West, Kevin was a postdoctoral fellow in the laboratory of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.

Kevin is a co-inventor on multiple patents and has published numerous scientific papers in leading peer-reviewed journals including Nature Medicine and Nature Biotechnology.

Legal Publications

  • Divided Infringement Challenges for Personalized Medicine, Daily Journal, June 2015
  • Burdens of Section 101 following Myriad, Daily Journal, October 2013
  • Containing Myriad, The Recorder, August 2013
  • Monoclonal Antibody Patents: Evolving Law & Strategies, Intellectual Property & Technology Law Journal, October 2012

Scientific Publications

  • Human SOCS1 controls immunostimulatory activity of monocyte-derived dendritic cells, Cancer Research, 2009 Oct. 15;69(20):8076-84
  • A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression, Nature Medicine, 2008 Mar.:14(3):258-265
  • Dendritic cell-based tumor vaccines and antigen presentation attenuators, Molecular Therapy, 2006 May;13(5):850-8
  • Inhibition of antigen presentation attenuators to augment vaccines, Current Opinion in Molecular Therapeutics, 2006 Feb.;8(1):24-30
  • SOCS1 restricts dendritic cell's ability to break self-tolerance and induce anti-tumor immunity by controlling IL-12 production and signaling, Journal of Clinical Investigation, 2006 Jan.;116(1):90-100
  • An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells, PLoS Medicine, 2006 Jan.:3(1)e11
  • Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity, Nature Biotechnology, 2004 Dec.;22(12):1546-53
 

About Kevin